ArticleEuropean journal of medical research2025
Sedation for transthoracic echocardiography in children with Down syndrome: a propensity score-weighted retrospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransthoracic echocardiography can be performed under sedation in children with Down syndrome who have neurological or behavioral problems. This study aimed to compare the efficacy and safety of intranasal dexmedetomidine and oral chloral hydrate in children with Down syndrome who are undergoing transthoracic echocardiography.
methodsThis retrospective cohort study reviewed the electronic medical records of patients with Down syndrome who underwent transthoracic echocardiography under oral chloral hydrate or intranasal dexmedetomidine sedation between June 2014 and September 2021. The patients were divided into oral chloral hydrate and intranasal dexmedetomidine groups according to the main agents used for sedation. The primary endpoint was the outcome of single-dose sedative agents, and the groups were compared using a propensity score weighting analysis.
resultsIn total, 149 patients (chloral hydrate group, n = 75; dexmedetomidine group, n = 74) were included in the final analysis. After propensity score weighting, 150 and 148 patients were included in the chloral hydrate and dexmedetomidine groups, respectively. The success rate of the initial sedative medication was significantly higher in the dexmedetomidine group than in the chloral hydrate group (89.1% vs. 80.7%, p = 0.0412) after adjustment for propensity score weighting. The success rate of the final sedative medication was higher in the dexmedetomidine group than in the chloral hydrate group (before propensity score weighting, 98.7% vs. 86.7%; after propensity score weighting, 98.5% vs. 86.8%; both p values < 0.01). Before and after propensity score weighting, the incidence of bradycardia during sleep was significantly higher in the dexmedetomidine group than in the chloral hydrate group. Sedation with dexmedetomidine or chloral hydrate was not associated with severe oxygen desaturation in children with Down syndrome.
conclusionsCompared with oral 50 mg/kg chloral hydrate, the use of a single intranasal dose of 2 μg/kg dexmedetomidine was related to a significantly higher success rate of sedation without increasing severe hypoxic events in children with Down syndrome undergoing transthoracic echocardiography, except for the incidence of bradycardia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.